GTC
Ghost Tree Capital Portfolio holdings
AUM
$276M
This Quarter Return
+7.52%
1 Year Return
+49.13%
3 Year Return
+198.45%
5 Year Return
+1,783.74%
10 Year Return
+9,775.89%
AUM
$357M
AUM Growth
+$357M
(-11%)
Cap. Flow
+$1.9M
Cap. Flow
% of AUM
0.53%
Top 10 Holdings %
Top 10 Hldgs %
48.05%
Holding
58
New
14
Increased
10
Reduced
11
Closed
8
Top Buys
| 1 |
Kura Oncology
KURA
|
$7.77M |
| 2 |
iShares Russell 2000 ETF
IWM
|
$6.63M |
| 3 |
Celldex Therapeutics
CLDX
|
$5.15M |
| 4 |
ESSA Pharma
EPIX
|
$5.08M |
| 5 |
Gyre Therapeutics
GYRE
|
$5.04M |
Top Sells
| 1 |
Travere Therapeutics
TVTX
|
$12.9M |
| 2 |
SURF
Surface Oncology, Inc. Common Stock
SURF
|
$9.24M |
| 3 |
FPRX
Five Prime Therapeutics, Inc.
FPRX
|
$8.51M |
| 4 |
CNST
Constellation Pharmaceuticals, Inc.
CNST
|
$8.19M |
| 5 |
Rocket Pharmaceuticals
RCKT
|
$7.76M |
Sector Composition
| 1 | Healthcare | 92.27% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Syndax Pharmaceuticals
SNDX
$1.41B
| $26.3M | 6.18% | 1,175,000 -175,000 | -13% | -$3.91M |
|
|
TRIL
2
DELISTED
Trillium Therapeutics Inc.
TRIL
| $20.9M | 4.92% | 1,950,000 | – | – |
|
3
Ascendis Pharma
ASND
$11.8B
| $17.4M | 4.09% | 135,000 +30,000 | +29% | +$3.87M |
|
|
4
Kura Oncology
KURA
$686M
| $17M | 3.99% | 600,000 +275,000 | +85% | +$7.77M |
|
5
Iovance Biotherapeutics
IOVA
$807M
| $15.8M | 3.72% | 500,000 | – | – |
|
6
Fate Therapeutics
FATE
$120M
| $15.3M | 3.58% | 185,000 +20,000 | +12% | +$1.65M |
|
7
Xenon Pharmaceuticals
XENE
$2.98B
| $15.2M | 3.58% | 850,000 +150,000 | +21% | +$2.69M |
|
8
Aclaris Therapeutics
ACRS
$209M
| $15.1M | 3.55% | 600,000 -50,000 | -8% | -$1.26M |
|
|
9
Rocket Pharmaceuticals
RCKT
$354M
| $14.4M | 3.39% | 325,000 -175,000 | -35% | -$7.76M |
|
10
Cogent Biosciences
COGT
$1.69B
| $14M | 3.3% | 1,600,000 +500,000 | +45% | +$4.39M |
|
11
Arvinas
ARVN
$568M
| $13.6M | 3.18% | 205,000 | – | – |
|
12
Apellis Pharmaceuticals
APLS
$3.48B
| $9.66M | 2.27% | 225,000 -100,000 | -31% | -$4.29M |
|
13
TG Therapeutics
TGTX
$4.65B
| $9.64M | 2.27% | 200,000 -50,000 | -20% | -$2.41M |
|
14
VistaGen Therapeutics
VTGN
$102M
| $8.83M | 2.07% | 4,143,702 +1,703,702 | +70% | +$3.63M |
|
|
MRTX
15
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $8.57M | 2.01% | 50,000 | – | – |
|
|
VRNA
16
Verona Pharma
VRNA
$9.16B
| $7.85M | 1.85% | 939,043 +129,043 | +16% | +$1.08M |
|
17
Aldeyra Therapeutics
ALDX
$351M
| $7.72M | 1.81% | 650,000 | – | – |
|
18
Mersana Therapeutics
MRSN
$36.5M
| $7.28M | 1.71% | 450,000 -150,000 | -25% | -$2.43M |
|
|
ISEE
19
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $6.95M | 1.63% | 1,125,000 -250,000 | -18% | -$1.55M |
|
|
20
iShares Russell 2000 ETF
IWM
$67B
| $6.63M | 1.56% | +30,000 | New | +$6.63M |
|
|
CNST
21
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
| $6.43M | 1.51% | 275,000 -350,000 | -56% | -$8.19M |
|
22
Biogen
BIIB
$19.4B
| $5.6M | 1.32% | 20,000 +17,800 | +809% | +$4.98M |
|
|
23
Celldex Therapeutics
CLDX
$1.47B
| $5.15M | 1.21% | +250,000 | New | +$5.15M |
|
|
STSA
24
DELISTED
Satsuma Pharmaceuticals, Inc. Common Stock
STSA
| $5.14M | 1.21% | 904,225 +704,225 | +352% | +$4M |
|
25
MoonLake Immunotherapeutics
MLTX
$3.54B
| $5.12M | 1.2% | 500,000 | – | – |
|